Loading
companiesCompany
TYK Medicines
TYK Medicines is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the EGFR inhibitor asandeutertinib (TY-9591) and TYK-00540 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and brain and spinal cord tumours.
Also called: Zhejiang Tongyuankang Pharmaceutical同源康医药
Overview
TYK Medicines (Zhejiang Tongyuankang) is a Chinese biotechnology company listed in Hong Kong that discovers, develops and manufactures small-molecule targeted cancer drugs, with research centres in Changxing and Zhengzhou. Its EGFR inhibitor asandeutertinib (TY-9591) has been approved in China for EGFR-mutant lung cancer with brain metastases. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (1 in phase 3 or 2/3): FLETEO (phase 3, Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Ce...), NCT06950086 (phase 1/2, Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors) and NCT05948813 (phase 2, TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#106of 1244 companies, score 50
- approved products +6
- phase 3 +3
- targets +2
- modalities +2
- regions +7
- registry trials +30
1 approved, 1 in phase 3, 0 earlier, 1 targets, 235 registry studies. Formula on the scorecards page.
Type
Biotech · HKEX:2410
Stage
Public
Website
Founded
2017
Phase 3small molecule (structure undisclosed or not yet in PubChem)
TY-9591 is an experimental small-molecule drug from TYK Medicines in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.
Similar pages
- TrialA Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Shares Osimertinib, Non-small-cell lung cancer.
- TrialJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Shares Osimertinib, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Osimertinib, Non-small-cell lung cancer.
- TrialA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Shares Osimertinib, Non-small-cell lung cancer.
cancers
drugs
ApprovedSmall-molecule kinase inhibitor (EGFR)
Osimertinib · Tagrisso
Phase 3small molecule (structure undisclosed or not yet in PubChem)